Caris Life Sciences initiated with an Outperform at Baird

Baird initiated coverage of Caris Life Sciences (CAI) with an Outperform rating and $26 price target Caris is a commercial-stage precision oncology company focused on improving patient outcomes through comprehensive molecular information and machine learning algorithms, the analyst tells investors in a research note. The firm says that while it sees some uncertainty around the company’s pipeline offerings and the consensus estimates for 2026, it thinks the recent stock selloff has created an attractive entry point.